FASN and fatty liver disease: IL-1βis known to promote hepatic steatosis by enhancing lipogenic pathways,particularly through the upregulation of fatty acid synthase, essentialfor triglyceride synthesis in the liver.42,43 Correspondingly, cytokine analysis indicated a reduction in IL-1βlevels in both serum (Figure 4D) and hepatic tissues (Figure 4E) in the LR069 and LB031 treatment groups.